REGENXBIO CEO Ken Mills Shines Light on Promising Phase I Trials for Wet AMD Gene Therapy RGX-314

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 190″]

REGENXBIO founding CEO Ken Mills reviews the company’s recent positive Phase I results for RGX-314, a potentially game-changing gene therapy for wet AMD. Mills also shares the responsibility he feels leading a pioneer in the blockbuster gene therapy field.